Lyterian Therapeutics is a biotechnology company focused on developing small molecule therapies for Alzheimer's disease and other age-related disorders. The company targets protein homeostasis and cellular clearance mechanisms that become dysregulated with aging and contribute to neurodegenerative pathology["@lyterian"].
...
Overview
Mermaid diagram (expand to render)
Lyterian Therapeutics is a biotechnology company focused on developing small molecule therapies for Alzheimer's disease and other age-related disorders. The company targets protein homeostasis and cellular clearance mechanisms that become dysregulated with aging and contribute to neurodegenerative pathology["@lyterian"].
The company's approach centers on enhancing the cell's natural ability to clear misfolded proteins—including amyloid-beta, tau, and alpha-synuclein—through modulation of autophagy and related protein clearance pathways. This mechanism-based strategy addresses the root cause of protein aggregation rather than just symptom management.
Corporate Profile
Headquarters: United States
Founded: 2020s
Focus: Small molecule modulators of protein homeostasis
Therapeutic Areas: Alzheimer's Disease, Parkinson's Disease, other age-related neurodegenerative disorders
Pipeline / Products
| Program | Target/Mechanism | Indication | Phase | Status | |---------|-----------------|------------|-------|--------| | LT-001 | Protein homeostasis modulator | Alzheimer's Disease | Preclinical | IND-enabling | | LT-002 | Autophagy enhancer | Parkinson's Disease | Preclinical | Research |
LT-001 (Lead Candidate)
LT-001 is Lyterian's lead clinical candidate for Alzheimer's disease. This small molecule modulator targets protein homeostasis pathways to enhance clearance of misfolded proteins:
Mechanism: Modulates autophagy-lysosomal and ubiquitin-proteasome pathways to increase cellular clearance of toxic protein aggregates
Target: Amyloid-beta and tau pathology in Alzheimer's disease
Status: IND-enabling studies, anticipated to enter Phase 1 clinical trials
Rationale: By enhancing the cell's natural clearance mechanisms, LT-001 aims to reduce amyloid plaque and tau tangle burden
LT-002
LT-002 is a preclinical candidate targeting Parkinson's disease:
Mechanism: Autophagy enhancement to clear alpha-synuclein aggregates
Target: Lewy body pathology in Parkinson's disease
Status: Research stage
Science & Technology Platform
Lyterian develops small molecules that modulate protein homeostasis pathways, including:
Autophagy Enhancement
Autophagy (self-eating) is a cellular process that degrades and recycles damaged proteins and organelles. In neurodegenerative diseases, autophagy becomes impaired, leading to accumulation of toxic protein aggregates. Lyterian's small molecules aim to restore autophagic flux[@autophagy]:
mTOR-independent pathways: Targeting proteins like Beclin-1 and AMBRA1
Combination potential: Can be combined with other modalities
Funding & Financials
2023: Series A funding to advance lead programs toward clinical development
2024: Expansion into targeted protein degradation for neurodegeneration
Scientific Advisory Board
Lyterian's scientific advisory board includes experts in autophagy, protein aggregation, and neurodegenerative disease research from leading academic institutions.
Competitive Landscape
Lyterian competes with other companies developing autophagy-enhancing approaches:
Gain Therapeutics — Novel small molecule proteostasis modulators